When we restricted our analysis to ER+HER2− breast cancer, the results similarly indicated a protective effect of chemotherapy in the high-risk (HR = 0.62, p = 8.0E−4, Table 2) and intermediate-risk group (HR = 0.79, p = 0.01, Table 2). Here, ESR1 is linked to breast cancer.